The trajectory of Viagra presents a complex case for investors in the pharmaceutical sector. While initially a tremendous success, producing vast sums, the intellectual property end and the subsequent arrival of off-brand versions have drastically impacted revenue. This presents questions about the future sustainability of related medication innova